Karo Healthcare acquired by KKR
Context
KKR has finalized the 100% acquisition of Karo Healthcare from the EQT VIII fund in a transaction initially announced in April 2025. The strategic rationale for KKR is to capitalize on a pan-European platform already structured for significant scale. Following a period where revenues quadrupled under EQT, Karo is entering an international acceleration phase. KKR plans to leverage its global footprint to deepen Karo’s reach across new distribution channels and geographies, while continuing to consolidate the fragmented sector through targeted bolt-on acquisitions. The transaction was advised by Citigroup and J.P. Morgan for KKR, and Morgan Stanley and Jefferies for EQT.
The acquisition of Karo Healthcare is part of the growth strategy of KKR, which already has several external growth operations under its belt, notably Spectris in 2025.
Karo Healthcare, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.
-> Deep-dive in Retail & Consumer market trends
Target
Karo Healthcare is a leading European platform specialized in over-the-counter (OTC) consumer healthcare products. Under EQT's ownership, the company underwent a radical transformation, evolving from a Nordic specialty pharma player into a pan-European champion. Its portfolio focuses on trusted brands in resilient categories: Skin Health, Foot Health, Intimate Health, Digestive Health, and Vitamins, Minerals & Supplements (VMS). Present in over 90 countries, Karo relies on a highly digitized commercial platform and a mixed growth model combining organic performance with an aggressive "Buy-and-Build" strategy, evidenced by eight acquisitions completed since 2019.
Ent. Value
€1–10bn
Equity Value
[members only]
Multiples
EV / Revenue
2x–6x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with KKR
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | KKR / ENERGY CAPITAL PARTNERS | DCC ENERGY | IRELAND | Downstream (Refining & Retail) |
| 12/2025 | KKR | WELLA | SWITZERLAND | Hygiene & Beauty Brands |
| 07/2025 | KKR | SPECTRIS | UNITED KINGDOM | Lab & Scientific Equipment |
| 11/2024 | KKR | GREENVOLT | PORTUGAL | Solar / PV |
| 10/2024 | KKR / KREFELD | ANJAC BEAUTY & HEALTH | FRANCE | CDMO |
| 10/2024 | ORANGE / CINVEN / KKR | MASORANGE | SPAIN | Operators |
| 06/2024 | KKR | ENCAVIS | GERMANY | Solar / PV |
| 10/2023 | KKR | CIRCOR INTERNATIONAL | UNITED STATES | Valves, Pumps & Taps |
| 07/2023 | KKR / MUBADALA | COOLIT SYSTEMS | CANADA | Servers & Networks |
| 12/2022 | KKR | APRIL | FRANCE | Brokerage |
Similar deals in Consumer Products
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2025 | ID UNLIMITED | POLYGRAPHIC | NETHERLANDS | Other Sports |
| 09/2025 | PLATINUM EQUITY | XD CONNECTS | NETHERLANDS | Consumer Products |
| 06/2025 | PARTNERS GROUP | MPM | UNITED KINGDOM | Pet Care |
| 06/2025 | PLATINUM EQUITY | SOLO GROUP | FRANCE | Consumer Products |
| 06/2025 | KONTOOR BRANDS | HELLY HANSEN | NORWAY | Fashion & Apparel |
| 05/2025 | AUTHENTIC BRANDS GROUP | DOCKERS | UNITED STATES | Fashion & Apparel |
| 04/2025 | BRICONORD | SCELL-IT | FRANCE | Home & DIY |
| 03/2025 | USHOPAL GROUP | PAYOT | FRANCE | Hygiene & Beauty Brands |
| 02/2025 | BC PARTNERS | PETLAB | UNITED KINGDOM | Pet Care |
| 01/2025 | ACON INVESTMENTS | TRUE RELIGION | UNITED STATES | Fashion & Apparel |
REFERENCES
Valuation range: EV €1–10bn
Revenue range: €450–900M
EBITDA range: €100–200M
EV/Revenue range: 2x - 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Karo Healthcare by KKR are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
FAQ
What transaction does this page cover?
How was the acquisition of Karo Healthcare by KKR valued, and what multiples were paid?
What were Karo Healthcare’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?